Summary
EudraCT Number: 2004-001503-36
Sponsor's Protocol Code Number: PROT25186
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2004-10-14
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001503-36/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2004-001503-36
A.3 Full title of the trial: Lutropin alfa (Luveris) in mid follicular phase for controlled ovarian stimulation (COS) in ovarian ageing: a randomised, comparative with parallel control group, phase II clinical trial.
A.3.2 Name or abbreviated title of the trial where available: Lutropin alfa in mid follicular phase
A.4.1 Sponsor's protocol code number: PROT25186
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: SERONO ESPAÑA, S.A.
B.1.3.4	Country: Spain
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.1.1.1 Trade name: LUVERIS
D.2.1.1.2 Name of the Marketing Authorisation holder: SERONO EUROPE LIMITED
D.2.1.2 Country which granted the Marketing Authorisation: Spain
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: LUVERIS 75 UI
D.3.2 Product code: Not Applicable
D.3.4 Pharmaceutical form: Powder and solvent for solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Lutropin alfa
D.3.9.3 Other descriptive name: r-hLH, recombinant human luteinizing hormone
D.3.10 Strength
D.3.10.1 Concentration unit: IU international unit(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 75 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Information not present in EudraCT
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: Yes
D.3.11.13.1 Other medicinal product type: Recombinant product 

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Controlled ovarian stimulation in women with ovarian ageing
PT: Assisted Fertilisation
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 7.0
E.1.2 Level: PT
E.1.2 Classification code: 10003539
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To assess the efficacy of mid-follicular addition of r-hLH versus no addition of r-hLH, in patients aged between 35 and 40 undergoing controlled ovarian stimulation with r-hFSH priot to IVF / ICSI and ET, in terms of oocyte quality as well as follicular development, oocyte fertilization, embryo quality and pregnancy rates.
E.2.2 Secondary objectives of the trial: To assess the safety of using r-hLH in combination with r-hFSH in this indication, including incidence of ovarian hyperstimulation syndrome (OHSS) and adverse events as well as local tolerance
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: 1)	Pre-menopausal woman, aged between 35 and 40 years of age inclusive, wishing to conceive.
2)	Baseline (early follicular, day 2-5) FSH serum level £ 10 IU/l assessed within the past 6 months as well as LH and E2 levels within local normal range. 
3)	Having regular spontaneous menstrual cycle lasting 25-35 days.
4)	Infertility justifying IVF/ET or ICSI treatment.
5)	Controlled ovarian stimulation with r-hFSH under long GnRH agonist protocol.

E.4 Principal exclusion criteria: 1)	Known to be HIV, HBV/HCV positive.
2)	Any clinically significant systemic disease; tumours of the hypothalamus and pituitary gland; ovarian, uterine or mammary cancer; hormonal abnormality and/or  medical, biochemical, hematological condition which in the judgement of the investigator may interfere with gonadotropin treatment.
3)	More than 2 previous ART cycles
4)	Cancellation of two previous cycles.
5)	Cryopreserved embryos from previous ART cycles

E.5 End points
E.5.1 Primary end point(s): The proportion of metaphase II oocytes retrieved
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: Standard treatment without Luveris
E.8.3 The trial involves single site in the Member State concerned: Yes
E.8.4 The trial involves multiple sites in the Member State concerned: No
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: End of the trial: last visit of the last subject
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 8
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 8

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: No
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2004-10-14) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 124
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 124
F.4.2.2 In the whole clinical trial: 124

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2004-11-03
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2004-09-22

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2006-11-15

